Director Sherif Riad filed a Form 4 with the SEC on November 10, 2026, disclosing the grant of 28,000 restricted stock units and 88,000 stock options in Ocular Therapeutix, Inc. (NASDAQ:OCUL) on November 6, 2026.
Key Highlights
- RSU grant: Sherif Riad received 28,000 restricted stock units on November 6, 2026, at a price of $0, acquired under transaction code A.
- Stock option grant: Riad also received 88,000 stock options with an exercise price of $6.60, expiring November 5, 2036, also at a derivative price of $0.
- Vesting schedule: Both the RSUs and stock options vest over three years, with one-third vesting on each yearly anniversary of the November 6, 2026 grant date, subject to continued board service.
- Plan: The RSUs were granted under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc.
- Resulting ownership: Following the transactions, Riad directly beneficially owns 28,000 shares of common stock and 88,000 derivative securities.
- Role: Riad is identified in the filing as a Director of Ocular Therapeutix, Inc.
Director Sherif Riad's November 2026 Equity Awards at Ocular Therapeutix
According to the Form 4 filed on November 10, 2026, Sherif Riad, a director of Ocular Therapeutix, Inc. (NASDAQ:OCUL), received two equity awards on November 6, 2026. The first was a grant of 28,000 restricted stock units under the company's 2021 Stock Incentive Plan, as amended. The filing states that each RSU "represents a right to receive one share of the Company's common stock." The acquisition is recorded at a price of $0, and the transaction code is listed as A (acquired).
The filing also discloses a grant of 88,000 stock options with a right-to-buy exercise price of $6.60 per share. The options carry an expiration date of November 5, 2036, and were also acquired at a derivative security price of $0. As with the RSUs, the transaction code is A. The filing states that both awards are subject to the same vesting terms: "the options will vest over three years, vesting 1/3 on each yearly anniversary of the date of grant," contingent on Riad's continued service on the company's board of directors.
Following both reported transactions, the filing indicates Riad directly holds 28,000 shares of common stock and 88,000 derivative securities. The Form 4 was signed by Todd Anderman as attorney-in-fact for Riad Sherif and submitted on November 10, 2026. No indirect ownership was reported.
What Was Disclosed
The filing reports two equity grants to director Sherif Riad on November 6, 2026: 28,000 RSUs and 88,000 stock options with a $6.60 exercise price, both vesting annually over three years under Ocular Therapeutix's 2021 Stock Incentive Plan.




Please wait processing your request...